LymeX Diagnostic Prize

A prize competition to accelerate the development of Lyme disease diagnostics

Phase 1 calls on scientific, technical, and clinical experts to submit innovative detection methods that will advance Lyme disease diagnostics.

About the competition

The goal of the LymeX Diagnostics Prize is to develop diagnostics that can accurately detect active Lyme disease infections in people. The multiphase competition will nurture the development of innovative solutions toward Food and Drug Administration review. Phase 1 will award $1 million. At the discretion of HHS and the Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2. Future phases are expected to focus on clinical and nonclinical validation of diagnostic test(s) that detect active infection by Lyme-disease-causing bacteria, as well as readiness for regulatory submission and market entry. Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Steven & Alexandra Cohen Foundation, $9 million in additional LymeX prizes are projected to be available to proposed future phases.

Phase 1 timeline

Phase 1 is open to all eligible entrants to submit concept papers and plans for development.

Competition launch

May 17, 2022

Submission deadline

August 8, 2022
We are here

Judging

Fall 2022

Phase 1 winner announcement

Fall 2022

Phase 2 launch

Late 2022

Phase 1 prizes

A judging panel will recommend up to 10 winners according to official Phase 1 evaluation criteria. Phase 1 winners will receive an equal share of the $1 million Phase 1 prize pool and will have the opportunity to participate in a planned Phase 2.

 

Note: No future phases or prizes are guaranteed beyond Phase 1. Future phases may be launched at the discretion of HHS and Cohen Foundation, and any prize amounts beyond Phase 1 are anticipated and subject to future availability of funds.

$1 million

With $10 million anticipated total prize pool planned across three phases

Submissions are closed.